| scholarly article | Q13442814 |
| P2093 | author name string | Emma Gray | |
| David J Pasta | |||
| Aisling O'Leary | |||
| Irish Hepatitis C Outcomes and Research Network (ICORN) | |||
| Suzanne Norris | |||
| P2860 | cites work | Predictors of the therapeutic response in hepatitis C. A 2013 update | Q38165490 |
| Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. | Q39352464 | ||
| Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort | Q40744923 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| Factors that predict response of patients with hepatitis C virus infection to boceprevir | Q42980646 | ||
| Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus | Q42984643 | ||
| Determination of the burden of hepatitis C virus infection in Ireland | Q43040601 | ||
| De testimonio: on the evidence for decisions about the use of therapeutic interventions | Q46612312 | ||
| Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. | Q51801410 | ||
| Importance of observational studies in clinical practice | Q57114036 | ||
| The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies | Q57266791 | ||
| Opportunities for minimization of confounding in observational research | Q82734824 | ||
| The value of observational research in liver diseases | Q83258931 | ||
| Can observational studies approximate RCTs? | Q83703960 | ||
| Comparative effectiveness research: what is it and why do we need it in nephrology? | Q84254092 | ||
| Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research | Q85156629 | ||
| Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 | ||
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. | Q30361098 | ||
| Importance of observational studies in clinical practice. | Q30366090 | ||
| Methods to adjust for bias and confounding in critical care health services research involving observational data | Q31036725 | ||
| Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. | Q31130672 | ||
| Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation | Q33204061 | ||
| Observational studies: a valuable source for data on the true value of RA therapies | Q33779130 | ||
| Study subjects and ordinary patients | Q34029400 | ||
| Study design, precision, and validity in observational studies | Q34059991 | ||
| The clinical relevance of observational research | Q34292554 | ||
| The challenge of selection bias and confounding in palliative care research | Q34315350 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies | Q34745086 | ||
| Representation of the elderly, women, and minorities in heart failure clinical trials | Q34769936 | ||
| Observational research methods. Research design II: cohort, cross sectional, and case-control studies | Q35047744 | ||
| Predictive factors associated with hepatitis C antiviral therapy response | Q35790397 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement | Q36988520 | ||
| A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. | Q37014369 | ||
| Understanding controlled trials. Why are randomised controlled trials important? | Q37150160 | ||
| Observational research--opportunities and limitations | Q37282191 | ||
| From randomized controlled trials to observational studies | Q37382509 | ||
| The role of observational investigations in comparative effectiveness research | Q37817499 | ||
| Hepatitis C: epidemiology, diagnosis, natural history and therapy. | Q37981869 | ||
| How to optimize HCV therapy in genotype 1 patients: predictors of response. | Q38071384 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 288 | |
| P577 | publication date | 2017-04-19 | |
| P1433 | published in | BMC Health Services Research | Q4835946 |
| P1476 | title | Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry | |
| P478 | volume | 17 |
Search more.